多西他赛联合替吉奥治疗晚期胃癌的临床疗效观察

目的：探讨多西他赛联合替吉奥治疗晚期胃癌的临床效果和安全性。方法选择2010年3月～2011年6月在我院治疗的138例晚期胃癌患者，随机分为两组，对照组接受临床一线治疗（DPF方案），实验组患者给予多西他赛联合替吉奥治疗，观察并比较两组患者的近期疗效及不良反应。结果治疗后，实验组和对照组患者的治疗总有效率分别为58.6％和41.2％，实验组显著高于对照组（P〈0.05）。治疗过程中，两组患者的主要不良反应包括脱发、恶心、呕吐、骨髓抑制、肝功能受损等，无心脏及肾脏的不良表现。实验组患者不良反应的发生率明显低于对照组（P〈0.05）。结论多西他赛联合替吉奥治疗晚期胃癌的临床效果更好，且毒副反应更少，具有更好的临床应用价值。

The Clinical Curative Efficacy of Docetaxel plus S-1 in the Treatment of Advanced Gastric Cancer

Objective To assess the efficacy and safety of docetaxel plus S-1 in the treatment of advanced gastric cancer. Methods From March 2010 to June 2011, 138 patients with advanced gastric cancer admitted in our hospital were selected and randomly divided into experimental group and control group. The control group was given front-line clinical treatment of DPF, while the experimental group was treated by docetaxel and S-1. The short-term efficacy and incidence of side-effects were ob-served and compared after treatment. Results The effective rate of the experimental group was significantly higher than that of the control group （58.6%vs. 41.2%, P〈0.05）. The main adverse reactions observed during treatment included hair loss, nausea, vom-iting, myelosuppression and liver function damage, while no adverse symptoms of heart or kidney was observed. The incidence of adverse reactions in experimental group was significantly lower than that in the control group （P〈0.05）. Conclusion Docetaxel plus S-1 was more effective and safer than the current front-line clinical DPF treatment in the treatment of advanced gastric cancer.